Report Description

Hypertrophic cardiomyopathy (HCM) is a disease of the heart muscles (myocardium) in which thickening of myocardium causes functional impairment. It is a genetic condition caused by mutation in one or more genes and is hereditary in nature. According to the European Society of Cardiology, prevalence of HCM was between 0.05% and 0.2% of the population in 2013. A study published in BioMed Central in 2010 stated that there was no significant gender and age range differences in the prevalence of HCM.
The global hypertrophic cardiomyopathy therapeutics market has been broadly categorized into drug class and geography. Beta adrenergic blocking agents, calcium channel blockers, antiarrhythmic agents, and anticoagulants together constitute the drugs class segment of the hypertrophic cardiomyopathy therapeutics market. Calcium channel blockers was the largest segment in 2014, although beta adrenergic blocking agents were the first choice for treatment of obstructive and non-obstructive HCM. Price of calcium channel blockers is higher than beta adrenergic blocking agents; hence, in terms of revenue, calcium channel blockers dominated the hypertrophic cardiomyopathy therapeutics market in 2014. A similar trend is expected to continue during the forecast period. Calcium channel blockers are anticipated to expand at a CAGR of 1.8% from 2015 to 2023.

Complete Report with TOC @ http://www.mrrse.com/hypertrophic-cardiomyopathy-therapeutics-market

Scope

Prevalence of HCM is higher among African-Americans compared to other races. The global hypertrophic cardiomyopathy therapeutics market was valued at USD 1,216.3 million in 2014 and is projected to reach USD 1,378.4 million by 2023, expanding at a CAGR of 1.4% during the forecast period.A similar trend is expected to continue during the forecast period. Calcium channel blockers are anticipated to expand at a CAGR of 1.8% from 2015 to 2023.

Key Players

AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG are some of the major companies operating in the global hypertrophic cardiomyopathy therapeutics market.

Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/1418

About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact
Corporate Office
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States

Tel: +1-518-618-1030
Email: sales@mrrse.com